Format

Send to

Choose Destination
Circulation. 2018 Jul 31;138(5):483-493. doi: 10.1161/CIRCULATIONAHA.117.033432.

Temporal Trends and Clinical Consequences of Wait Times for Transcatheter Aortic Valve Replacement.

Author information

1
Schulich Heart Centre, Division of Cardiology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada (G.E-G., D.T.K., H.C.W.).
2
Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada (S.M., J.F., D.T.K., H.C.W.).
3
Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada (D.T.K., H.C.W.).
4
Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada (D.T.K., H.C.W.).
5
Center for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, Canada (S.B.L., J.G.W.).
6
Division of Cardiovascular Disease and Department of Internal Medicine, University of Michigan, Ann Arbor, MI (B.K.N.).

Abstract

BACKGROUND:

Transcatheter aortic valve replacement (TAVR) represents a paradigm shift in the therapeutic options for patients with severe aortic stenosis. However, rapid and exponential growth in TAVR demand may overwhelm capacity, translating to inadequate access and prolonged wait times. Our objective was to evaluate temporal trends in TAVR wait times and the associated clinical consequences.

METHODS:

In this population-based study in Ontario, Canada, we identified all TAVR referrals from April 1, 2010, to March 31, 2016. The primary outcome was the median total wait time from referral to procedure. Piecewise regression analyses were performed to assess temporal trends in TAVR wait times, before and after provincial reimbursement in September 2012. Clinical outcomes included all-cause death and heart failure hospitalizations while on the wait list.

RESULTS:

The study cohort included 4461 referrals, of which 50% led to a TAVR, 39% were off-listed for other reasons, and 11% remained on the wait list at the conclusion of the study. For patients who underwent a TAVR, the estimated median wait time in the postreimbursement period stabilized at 80 days and has remained unchanged. The cumulative probability of wait-list mortality and heart failure hospitalization at 80 days was ≈2% and 12%, respectively, with a relatively constant increase in events with increased wait times.

CONCLUSIONS:

Postreimbursement wait time has remained unchanged for patients undergoing a TAVR procedure, suggesting the increase in capacity has kept pace with the increase in demand. The current wait time of almost 3 months is associated with important morbidity and mortality, suggesting a need for greater capacity and access.

KEYWORDS:

TAVR; transcatheter aortic valve replacement

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center